These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 32805066)

  • 1. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
    Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
    Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that
    Izumi H; Wang Z; Goto Y; Ando T; Wu X; Zhang X; Li H; Johnson DE; Grandis JR; Gutkind JS
    Mol Cancer Ther; 2020 Jul; 19(7):1562-1571. PubMed ID: 32430488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
    Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
    Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
    [No Abstract]   [Full Text] [Related]  

  • 5. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
    Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
    Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
    Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
    Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
    [No Abstract]   [Full Text] [Related]  

  • 8. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of SPP1 as a prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma.
    Cai X; Zhang H; Li T
    Int J Oral Maxillofac Surg; 2022 Jun; 51(6):732-741. PubMed ID: 34489157
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Benedetto R; Massicano AVF; Crenshaw BK; Oliveira R; Reis RM; Araújo EB; Lapi SE
    Cancer Biother Radiopharm; 2019 Jun; 34(5):288-296. PubMed ID: 30865493
    [No Abstract]   [Full Text] [Related]  

  • 12. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.
    Jiang Y; Cao W; Wu K; Qin X; Wang X; Li Y; Yu B; Zhang Z; Wang X; Yan M; Xu Q; Zhang J; Chen W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):365. PubMed ID: 31429766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
    Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
    Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.
    Shimizu R; Ibaragi S; Eguchi T; Kuwajima D; Kodama S; Nishioka T; Okui T; Obata K; Takabatake K; Kawai H; Ono K; Okamoto K; Nagatsuka H; Sasaki A
    Int J Oncol; 2019 Jan; 54(1):283-294. PubMed ID: 30431077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.
    Novoplansky O; Fury M; Prasad M; Yegodayev K; Zorea J; Cohen L; Pelossof R; Cohen L; Katabi N; Cecchi F; Joshua BZ; Popovtzer A; Baselga J; Scaltriti M; Elkabets M
    Int J Cancer; 2019 Aug; 145(3):748-762. PubMed ID: 30694565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
    Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
    Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
    Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
    PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET inhibitor suppresses melanoma progression
    Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
    Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
    Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
    Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.